Maravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $56.6 million versus the consensus estimate of $56.67 million.

Financial Guidance for 2025

Maravai intends to provide certain financial guidance for 2025 during its financial results conference call on March 20, 2025 at 2:00 p.m. Pacific Time.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.